Navigation Links
A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.

BOLDON, England, January 14 /PRNewswire/ -- IDS is pleased to announce that their new, unique immunoassay Rat/Mouse PINP- the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*, is now available.

The IDS Rat/Mouse P1NP is the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*. The use of this assay will aid the assessment of new osteoporosis drug candidates in pre-clinical studies and is therefore ideal for Pharmaceutical, Clinical and Academic Research Organizations alike.

The IDS Rat/Mouse PINP EIA is very flexible and measures PINP released from collagen synthesis in rats or mice (plasma or serum). The cross-reactivity with human-derived P1NP is not detectable.

The assay is very simple to perform and results are available in under 3 hours. The assay format and quality also allows one operator to perform over 160 tests per day ensuring high sample throughput and precise, sensitive results.

The combination of 8 well microtiter strips and up to 12 months shelf life also makes this kit ideal for academic researchers with low sample throughput providing quicker and more cost-effective results.

The IDS PINP EIA further expands the range what we believe to be the largest range of Bone & Cartilage Immunoassays available globally.

* Additional Information

The generation of type I collagen is a crucial step in bone formation where type I collagen is the major organic component of bone matrix. Propeptides are cleaved from both the N- and C-terminal ends of the procollagen molecule in equimolar concentrations during collagen synthesis. Thus, the quantification of N-terminal propeptide of type I procollagen (PINP) provides measurement of collagen synthesis and/or bone formation.


Dean Hutchinson

Head of Marketing,


Telephone: +44(0)191-519-6104

Fax: +44(0)191-519-0760


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest
2. Study Reaffirms Superiority of Trofile(TM) Assay
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
5. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
6. Assay Designs(TM) Announces Additions to the Leadership Team
7. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
Breaking Biology News(10 mins):